Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease.
Open Access
- 1 February 1992
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 175 (2), 405-413
- https://doi.org/10.1084/jem.175.2.405
Abstract
In this report we have investigated macrophage (M phi) activity and tumor necrosis factor alpha (TNF-alpha) production during graft-vs.-host disease (GVHD). TNF-alpha production by M phi requires two signals: priming of M phi by interferon followed by triggering of TNF-alpha production and release by lipopolysaccharide (LPS). The state of M phi activation was examined in nonirradiated B6AF1 recipient mice injected with either 60 x 10(6) (acute GVHD) or 30 x 10(6) (nonlethal GVHD) parental B6 lymphoid cells. During the early phase of acute GVHD, administration of normally sublethal amounts of LPS-triggered release of significant amounts of TNF-alpha into the serum resulting in death of the animals within 36 h. Normal animals treated with the same dose of LPS neither died nor produced detectable amounts of serum TNF-alpha. In vitro studies demonstrated that M phi were primed during GVHD. The level of M phi priming was greater during acute GVHD than nonlethal GVHD since 100-fold less LPS was required to trigger killing of a TNF-alpha-sensitive cell line by M phi from acute GVHD animals. The amount of TNF-alpha released into the serum after LPS injection increased during the course of the GVHD and was significantly greater in acute GVH-reactive mice. Endogenous LPS was detected in the serum of acute GVH-reactive animals coincident with the onset of mortality. The data provide evidence that during GVHD M phi are primed as a result of the allogeneic reaction and that endogenous LPS therefore triggers M phi production of TNF-alpha resulting in the symptoms characteristic of acute GVHD.Keywords
This publication has 58 references indexed in Scilit:
- Induction, Specificity and Elimination of Asialo‐GM 1+ Graft‐Versus‐Host Effector Cells of Donor OriginScandinavian Journal of Immunology, 1991
- Structure and Function of Lipopolysaccharide Binding ProteinScience, 1990
- PREVENTION OF MURINE GRAFT-VERSUS-HOST DISEASE BY INDUCING AND ELIMINATING ASGM1+ CELLS OF DONOR ORIGINTransplantation, 1988
- Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease.The Journal of Experimental Medicine, 1987
- INTERFERON α/β SYNTHESIS DURING ACUTE GRAFT-VERSUS-HOST DISEASETransplantation, 1987
- Graft-versus-Host Disease and Survival in Patients with Aplastic Anemia Treated by Marrow Grafts from HLA-Identical SiblingsNew England Journal of Medicine, 1983
- Evidence for Two Types of Non-specific Suppressor Cells Activated by the Graft-versus-Host Reaction in MiceScandinavian Journal of Immunology, 1978
- Graft versus host-induced immunosuppression: Mechanism of depressed T-cell helper function in vitroCellular Immunology, 1977
- IMMUNOLOGIC INCOMPETENCE OF IMMUNOLOGICALLY RUNTED ANIMALSThe Journal of Experimental Medicine, 1964
- Increased Sensitivity to Bacterial Endotoxin of F 1 Hybrid Mice undergoing Graft-versus-Host ReactionNature, 1961